A Naturally Occurring Proline-to-Alanine Amino Acid Change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis Accounts for Reduced Echinocandin Susceptibility
暂无分享,去创建一个
[1] M. Cuenca‐Estrella,et al. Prevalence and Susceptibility Profile of Candida metapsilosis and Candida orthopsilosis: Results from Population-Based Surveillance of Candidemia in Spain , 2008, Antimicrobial Agents and Chemotherapy.
[2] G. Forrest,et al. Increasing incidence of Candida parapsilosis candidemia with caspofungin usage. , 2008, The Journal of infection.
[3] M. Pfaller,et al. Geographic and Temporal Trends in Isolation and Antifungal Susceptibility of Candida parapsilosis: a Global Assessment from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005 , 2008, Journal of Clinical Microbiology.
[4] M. Pfaller,et al. In Vitro Susceptibility of Invasive Isolates of Candida spp. to Anidulafungin, Caspofungin, and Micafungin: Six Years of Global Surveillance , 2007, Journal of Clinical Microbiology.
[5] B. Arthington-Skaggs,et al. Paradoxical Growth Effect of Caspofungin Observed on Biofilms and Planktonic Cells of Five Different Candida Species , 2007, Antimicrobial Agents and Chemotherapy.
[6] D. Perlin. Resistance to echinocandin-class antifungal drugs. , 2007, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.
[7] G. Butler,et al. Transcriptional Response of Candida parapsilosis following Exposure to Farnesol , 2007, Antimicrobial Agents and Chemotherapy.
[8] A. Colombo,et al. Prospective Observational Study of Candidemia in São Paulo, Brazil: Incidence Rate, Epidemiology, and Predictors of Mortality , 2007, Infection Control & Hospital Epidemiology.
[9] M. Pfaller,et al. Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem , 2007, Clinical Microbiology Reviews.
[10] M. Feldmesser,et al. Development of Candidemia on Caspofungin Therapy: a Case Report , 2006, Infection.
[11] M. Pfaller,et al. Global Surveillance of In Vitro Activity of Micafungin against Candida: a Comparison with Caspofungin by CLSI-Recommended Methods , 2006, Journal of Clinical Microbiology.
[12] J. Bennett. Echinocandins for candidemia in adults without neutropenia. , 2006, The New England journal of medicine.
[13] Benjamin J Park,et al. Epidemiology of Candidemia in Brazil: a Nationwide Sentinel Surveillance of Candidemia in Eleven Medical Centers , 2006, Journal of Clinical Microbiology.
[14] S. Katiyar,et al. Candida albicans and Candida glabrata Clinical Isolates Exhibiting Reduced Echinocandin Susceptibility , 2006, Antimicrobial Agents and Chemotherapy.
[15] Sergey V. Balashov,et al. Assessing Resistance to the Echinocandin Antifungal Drug Caspofungin in Candida albicans by Profiling Mutations in FKS1 , 2006, Antimicrobial Agents and Chemotherapy.
[16] A. Colombo,et al. Clinical and microbiological aspects of candidemia due to Candida parapsilosis in Brazilian tertiary care hospitals. , 2006, Medical mycology.
[17] M. Cuenca‐Estrella,et al. Epidemiology, Risk Factors, and Prognosis of Candida parapsilosis Bloodstream Infections: Case-Control Population-Based Surveillance Study of Patients in Barcelona, Spain, from 2002 to 2003 , 2006, Journal of Clinical Microbiology.
[18] V. Morrison. Echinocandin antifungals: review and update , 2006, Expert review of anti-infective therapy.
[19] M. Pfaller,et al. In Vitro Susceptibilities of Candida spp. to Caspofungin: Four Years of Global Surveillance , 2006, Journal of Clinical Microbiology.
[20] M. Pfaller,et al. In Vitro Activities of Anidulafungin against More than 2,500 Clinical Isolates of Candida spp., Including 315 Isolates Resistant to Fluconazole , 2005, Journal of Clinical Microbiology.
[21] S. Katiyar,et al. Promoter-dependent disruption of genes: simple, rapid, and specific PCR-based method with application to three different yeast , 2005, Current Genetics.
[22] S. A. Parent,et al. Specific Substitutions in the Echinocandin Target Fks1p Account for Reduced Susceptibility of Rare Laboratory and Clinical Candida sp. Isolates , 2005, Antimicrobial Agents and Chemotherapy.
[23] M. Maiden,et al. Candida orthopsilosis and Candida metapsilosis spp. nov. To Replace Candida parapsilosis Groups II and III , 2005, Journal of Clinical Microbiology.
[24] J. Perfect,et al. Interlaboratory Comparison of Results of Susceptibility Testing with Caspofungin against Candida and Aspergillus Species , 2004, Journal of Clinical Microbiology.
[25] A. Safdar,et al. The predictors of outcome in immunocompetent patients with hematogenous candidiasis. , 2004, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.
[26] A. Espinel-Ingroff. In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature. , 2003, Revista iberoamericana de micologia.
[27] D. Denning. Echinocandin antifungal drugs , 2003, The Lancet.
[28] N. Wiederhold,et al. The echinocandin antifungals: an overview of the pharmacology, spectrum and clinical efficacy , 2003, Expert opinion on investigational drugs.
[29] T. Edlind,et al. Histone Deacetylase Inhibitors Enhance Candida albicans Sensitivity to Azoles and Related Antifungals: Correlation with Reduction in CDR and ERG Upregulation , 2002, Antimicrobial Agents and Chemotherapy.
[30] D. Armstrong,et al. Hematogenous infections due to Candida parapsilosis: changing trends in fungemic patients at a comprehensive cancer center during the last four decades. , 2002, Diagnostic microbiology and infectious disease.
[31] L. Saiman,et al. Risk factors for Candida species colonization of neonatal intensive care unit patients. , 2001, The Pediatric infectious disease journal.
[32] M. Pfaffl,et al. A new mathematical model for relative quantification in real-time RT-PCR. , 2001, Nucleic acids research.
[33] A. Mitchell,et al. Identification of the FKS1 gene of Candida albicans as the essential target of 1,3-beta-D-glucan synthase inhibitors , 1997, Antimicrobial agents and chemotherapy.
[34] N. Morin,et al. Differential expression and function of two homologous subunits of yeast 1,3-beta-D-glucan synthase , 1995, Molecular and cellular biology.
[35] N. Morin,et al. The Saccharomyces cerevisiae FKS1 (ETG1) gene encodes an integral membrane protein which is a subunit of 1,3-beta-D-glucan synthase. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[36] Clinical,et al. Reference method for broth dilution antifungal susceptibility testing of yeasts : Approved standard , 2008 .